3 results
Primary Objectives:*Phase 0: To determine the receptor occupancy of OPN-305 1.5mg/kg in patients receiving an ECD, DCD or SCD(CIT>18h) kidney transplantation and to verify the doses of OPN-305 to be used in Part A of the study.*Part A: to…
To assess out to one-year the clinical status of patients who completed the double-blind part B of the 6-month study period in the Opsona phase II protocol (OPN305-102) by recording the following:• Incidence of biopsy-proven allograft rejection or…
In this study, we will investigate how quickly and to what extent etrumadenant is absorbed, transported, and eliminated from the body. For this study, etrumadenant is radioactively labelled with carbon 14 (14C). In this way, etrumadenant can be…